3-Dimethylaminopropylchloride hydrochloride

We are 3-Dimethylaminopropylchloride hydrochloride CAS:5407-04-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-Dimethylaminopropylchloride hydrochloride
CAS.NO:5407-04-5
Synonyms:3-Dimethylaminopropylchloride hydrochloride
3-dimethylaminoprop-1-yl chloride hydrochloride
3-Chloro-N,N-dimethylpropylamine
3-Dimethylamino-1-propyl chloride hydrochloride
3-Chloro-N,N-dimethylpropylamine Hydrochloride
3-chloro-N,N-dimethylaminopropane hydrochloride
 
Physical and Chemical Properties:
Boiling Point 130.7ºC at 760mmHg
Melting Point 187-190 °C(lit.)
Molecular Formula C5H13Cl2N
Molecular Weight 158.069
Flash Point 32.8ºC
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Storage:Store in a cool, ventilated place
Application:Intermediate of Escitalopram(CAS:128196-01-0) and Citalopram(CAS:59729-33-8).

3-Dimethylaminopropylchloride hydrochloride


Related News: As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.2882-20-4 Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity.34036-80-1 In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.958-09-8 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.

Related Products
Product Name
(S)-2-(2-Oxopyrrolidin-1-yl)butanoic acid View Details
Dermcidin-1L(human) View Details
5-Bromo-2-methylbenzoic acid View Details
trans,trans-2,4-Heptadienal manufacturer 3-(diethylamino)phenol,sulfuric acid manufacturer 3-chloro-5,11-dihydrobenzo[b][1,4]benzodiazepin-6-one manufacturer (1R,2R)-(-)-1,2-Diaminocyclohexane manufacturer Ethyl 6-(4-aminophenyl)-1-(4-methoxyphenyl)-7-oxo-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxylate manufacturer